Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration
This post hoc analysis of 2 randomized clinical trials evaluates baseline and early treatment response factors associated with longer faricimab dosing intervals in patients with neovascular age-related macular degeneration.
Authors
- Priya S. Vakharia (ORCID: https://orcid.org/0000-0002-2962-3725)
- Benjamin Bakall (ORCID: https://orcid.org/0000-0003-1143-3007)
- Mathias M. Maier (ORCID: https://orcid.org/0000-0003-4165-4003)
- Deepak Sambhara (ORCID: https://orcid.org/0009-0000-2627-5203)
- Eric H. Souied (ORCID: https://orcid.org/0000-0001-9388-202X)
- Philippe Margaron (ORCID: https://orcid.org/0000-0001-5215-3373)
- Quresh Amir Mohamed
- Adrian Hock Chuan Koh (ORCID: https://orcid.org/0009-0004-3275-5683)
- C K Tan
- Shriji Patel
- Ming Yang
Institutions
- Roche (Switzerland) (CH)
- Genentech
- Université Paris-Est Créteil (FR)
- Gloucestershire Hospitals NHS Foundation Trust (GB)
- Tan Tock Seng Hospital (SG)
- TUM Klinikum (DE)
- Eye & Retina Surgeons (SG)
- Retina Vitreous Associates of Florida (US)
- National Healthcare Group (SG)
- University of Arizona College of Medicine- Phoenix (US)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2026-10-15
- DOI
- https://doi.org/10.1001/jamaophthalmol.2026.4385
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00